<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cradle cap and seborrheic dermatitis in infants</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cradle cap and seborrheic dermatitis in infants</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Cradle cap and seborrheic dermatitis in infants</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Denis Sasseville, MD, FRCPC</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Moise L Levy, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph Fowler, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 24, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H608072793"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Seborrheic dermatitis is a self-limiting eruption consisting of erythematous plaques with greasy-looking, yellowish scales or hypopigmented, scaly patches distributed on areas rich in sebaceous glands, such as the scalp  (<a class="graphic graphic_picture graphicRef101267 graphicRef101268 graphicRef130273" href="/d/graphic/101267.html" rel="external">picture 1A-C</a>), the external ear, the center of the face, and the intertriginous areas. </p><p>This topic will discuss cradle cap and seborrheic dermatitis in infants. Seborrheic dermatitis in adolescents and adults is discussed separately. (See  <a class="medical medical_review" href="/d/html/13669.html" rel="external">"Seborrheic dermatitis in adolescents and adults"</a>.)</p><p class="headingAnchor" id="H608072800"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Seborrheic dermatitis occurs in infants between the ages of 3 weeks and 12 months. It has been reported in approximately 10 percent of infants younger than one month [<a href="#rid1">1</a>]. The prevalence peaks at the age of three months (approximately 70 percent) and decreases steadily in the following months, affecting approximately 7 percent of children aged one to two years [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H608072807"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The pathogenesis of infantile seborrheic dermatitis is not known. Transplacental transfer of maternal androgens stimulates the growth of the infant's sebaceous glands, which are necessary but not sufficient for the development of seborrheic dermatitis. The role of <em>Malassezia</em>, a lipid-dependent yeast, is not clear. <em>Malassezia</em> colonization has been reported in infants with seborrheic dermatitis, infants with other dermatologic conditions, and in normal infants [<a href="#rid3">3-5</a>].</p><p class="headingAnchor" id="H608072814"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>The most common manifestation of seborrheic dermatitis in newborns and infants is "cradle cap," an asymptomatic and noninflammatory accumulation of yellowish, greasy scales on the scalp  (<a class="graphic graphic_picture graphicRef101267 graphicRef101268" href="/d/graphic/101267.html" rel="external">picture 1A-B</a>). The vertex and the frontal area are commonly involved. Sometimes the eruption starts on the face, with erythematous, scaly, salmon-colored plaques  (<a class="graphic graphic_picture graphicRef101269" href="/d/graphic/101269.html" rel="external">picture 2</a>). In infants with skin of color, seborrheic dermatitis may present with hypopigmented, scaly patches  (<a class="graphic graphic_picture graphicRef130273" href="/d/graphic/130273.html" rel="external">picture 1C</a>). The forehead, the retroauricular areas, eyebrows and eyelids, cheeks, and nasolabial folds are commonly affected  (<a class="graphic graphic_picture graphicRef101270" href="/d/graphic/101270.html" rel="external">picture 1D</a>). Seborrheic dermatitis may also occur in the napkin (diaper) area  (<a class="graphic graphic_picture graphicRef73813" href="/d/graphic/73813.html" rel="external">picture 3</a>), on the trunk, with a predilection for the umbilical area, or in the intertriginous areas. It also may occur simultaneously at multiple sites  (<a class="graphic graphic_picture graphicRef52803" href="/d/graphic/52803.html" rel="external">picture 4</a>). </p><p>In the folds around the neck, in the axillae, and the crural region, the lesions have a moist, glistening, nonscaly aspect and tend to be confluent. In more widespread forms, large areas of the trunk may become involved with sharply marginated plaques of erythema and scaling that cover the lower abdomen, pubic and groin area, as well as the buttocks. Rarely, seborrheic dermatitis may present as an erythrodermic eruption in infants [<a href="#rid6">6,7</a>].</p><p>The infant is generally well; feeding and sleep are not disturbed. The pruritus is mild in most cases. The clinical manifestations fluctuate, but most cases eventually resolve spontaneously within weeks to a few months. Cases persisting beyond the age of 12 months are rare and require the diagnosis to be reconsidered. (See <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H608072842"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Several inflammatory skin disorders may present in the infant with features resembling seborrheic dermatitis. In the evaluation of an infant with atypical seborrheic dermatitis that does not resolve with standard treatment, Langerhans cell histiocytosis should be considered in the differential diagnosis:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Atopic dermatitis</strong> – Atopic dermatitis is the other major dermatitis of infancy. It is characterized by severe pruritus that interferes with feeding and sleep. The erythematous, scaly, and crusted lesions of atopic dermatitis are generally poorly demarcated, and commonly involve the cheeks, scalp, and extensor surfaces of the limbs  (<a class="graphic graphic_picture graphicRef77386 graphicRef77457 graphicRef56461" href="/d/graphic/77386.html" rel="external">picture 5A-C</a>). The diaper area is usually spared  (<a class="graphic graphic_picture graphicRef68746" href="/d/graphic/68746.html" rel="external">picture 6</a>). A positive family history of eczema, asthma, and allergic rhinitis is often present. (See  <a class="medical medical_review" href="/d/html/1729.html" rel="external">"Atopic dermatitis (eczema): Pathogenesis, clinical manifestations, and diagnosis", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diaper dermatitis</strong> – Irritant diaper dermatitis is caused by the moist environment and friction of the diaper. In contrast to seborrheic dermatitis, it usually spares the skin folds. However, diaper dermatitis with superimposed <em>Candida</em> infection has a beefy red, glistening appearance, sometimes with superficial erosions, and involves the skin folds. Transient pustules may be seen at the advancing borders, and satellite lesions are common  (<a class="graphic graphic_picture graphicRef64556" href="/d/graphic/64556.html" rel="external">picture 7</a>). Infrequently, diaper dermatitis may spread beyond the diaper area and become disseminated, with a pattern resembling seborrheic dermatitis. (See  <a class="medical medical_review" href="/d/html/5795.html" rel="external">"Diaper dermatitis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Psoriasis</strong> – Psoriasis is uncommon in infants, but can mimic seborrheic dermatitis, especially when it involves the flexures or the diaper area. The psoriatic plaques are sharply defined, shiny and bright red in color, with the typical large, silvery scales of psoriasis usually seen in nonintertriginous areas  (<a class="graphic graphic_picture graphicRef74892" href="/d/graphic/74892.html" rel="external">picture 8</a>). (See  <a class="medical medical_review" href="/d/html/5664.html" rel="external">"Psoriasis: Epidemiology, clinical manifestations, and diagnosis", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Langerhans cell histiocytosis</strong> – Langerhans cell histiocytosis may present in infancy as a refractory seborrheic dermatitis or as diaper dermatitis with ulceration and erosion. Sometimes, papules and brownish-red or purpuric nodules can be seen on the scalp, retroauricular areas, axillae, and inguinocrural folds  (<a class="graphic graphic_picture graphicRef57722 graphicRef69504" href="/d/graphic/57722.html" rel="external">picture 9A-B</a>). A skin biopsy will confirm the diagnosis. (See  <a class="medical medical_review" href="/d/html/8385.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tinea capitis</strong> – In infants, tinea capitis may present as a scaly scalp dermatitis with moderate or minimal inflammation  (<a class="graphic graphic_picture graphicRef101271" href="/d/graphic/101271.html" rel="external">picture 10</a>). Hair loss generally is present but is not always easy to detect. KOH examination of the hair shaft and fungal cultures will confirm the diagnosis. Tinea is rare in infants. (See  <a class="medical medical_review" href="/d/html/99983.html" rel="external">"Tinea capitis"</a>.)</p><p></p><p class="headingAnchor" id="H608072935"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H710058552"><span class="h2">Cradle cap</span><span class="headingEndMark"> — </span>In infants, seborrheic dermatitis has a self-limited course and resolves spontaneously in weeks to several months. Therefore, we suggest that initial treatment should be conservative, including education and reassurance of parents/caregivers and simple skin care measures.</p><p>Conservative measures for scalp seborrheic dermatitis may include:</p><p class="bulletIndent1"><span class="glyph">●</span>Application of an emollient (white petrolatum, vegetable oil, <a class="drug drug_pediatric" data-topicid="12614" href="/d/drug information/12614.html" rel="external">mineral oil</a>, baby oil) to the scalp (overnight, if necessary) to loosen the scales, followed by removal of scales with a soft brush (eg, a soft toothbrush) or fine-tooth comb</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Frequent shampooing with mild, nonmedicated baby shampoo followed by removal of scales with a soft brush (eg, a soft toothbrush) or fine-tooth comb</p><p></p><p>In more extensive or persistent cases, we suggest a short course of low-potency topical corticosteroids (group 7  (<a class="graphic graphic_table graphicRef62402" href="/d/graphic/62402.html" rel="external">table 1</a>)) applied once per day for one week, <a class="drug drug_pediatric" data-topicid="13401" href="/d/drug information/13401.html" rel="external">ketoconazole</a> 2% shampoo twice per week for two weeks, or ketoconazole 2% cream once or twice daily for two weeks or until sufficient improvement is noted. Corticosteroids are preferred if there is a predominant inflammatory component; ketoconazole 2% cream or shampoo is an alternative in diffuse cases or if the use of topical corticosteroids is a concern for the parents/caregivers [<a href="#rid8">8</a>]. </p><p><a class="drug drug_pediatric" data-topicid="13401" href="/d/drug information/13401.html" rel="external">Ketoconazole</a> shampoo may cause eye irritation. The use of lower-potency topical corticosteroids in children is generally safe when used for short durations. (See  <a class="medical medical_review" href="/d/html/5565.html" rel="external">"Topical corticosteroids: Use and adverse effects"</a>.)</p><p>There are no randomized trials of antifungal agents or topical corticosteroids for the treatment of cradle cap in infants. In a nonrandomized study of 48 children aged two weeks to two years, <a class="drug drug_pediatric" data-topicid="13401" href="/d/drug information/13401.html" rel="external">ketoconazole</a> 2% cream was equivalent to 1% <a class="drug drug_pediatric" data-topicid="13361" href="/d/drug information/13361.html" rel="external">hydrocortisone</a> cream in clearing the lesions in two weeks [<a href="#rid9">9</a>].</p><p>Due to the scarcity of data concerning the safety of topical <a class="drug drug_pediatric" data-topicid="13401" href="/d/drug information/13401.html" rel="external">ketoconazole</a> in the pediatric population, the manufacturer of ketoconazole shampoo and cream recommends limiting its use to individuals older than 12 years of age, except under the advice of a clinician. In clinical practice, topical ketoconazole has been used in infants and children without adverse effects. Systemic absorption of topical ketoconazole in infants has been evaluated in two studies. In one, ketoconazole 2% shampoo used twice a week for four weeks in 13 infants (&lt;12 months) produced no detectable serum ketoconazole levels and no abnormalities of liver function tests [<a href="#rid10">10</a>]. In the other, ketoconazole 2% cream was used once daily for 10 days to treat 19 children with seborrheic dermatitis of the scalp and diaper area. Peak plasma levels of ketoconazole detected one to three hours after topical treatment were 1 to 2 percent of those measured after systemic administration [<a href="#rid11">11</a>]. </p><p>Other antiseborrheic shampoos (eg, <a class="drug drug_pediatric" data-topicid="12785" href="/d/drug information/12785.html" rel="external">selenium sulfide</a> 2.5%, <a class="drug drug_general" data-topicid="10237" href="/d/drug information/10237.html" rel="external">zinc pyrithione</a>, salicylic acid) have been used in the treatment of infantile seborrheic dermatitis. However, there are no clinical trials evaluating their efficacy and safety in infants. Observational studies in adults suggest that shampoos and ointments containing salicylic acid may result in systemic toxicity because of transcutaneous absorption [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H710058559"><span class="h2">Nonscalp, nonintertriginous seborrheic dermatitis</span><span class="headingEndMark"> — </span>We suggest that seborrheic dermatitis involving body areas other than the scalp in infants be treated with <a class="drug drug_pediatric" data-topicid="13401" href="/d/drug information/13401.html" rel="external">ketoconazole</a> 2% cream (once a day for one to two weeks) or a low-potency topical corticosteroid (eg, <a class="drug drug_pediatric" data-topicid="13361" href="/d/drug information/13361.html" rel="external">hydrocortisone</a> 1% cream once a day). The use of topical corticosteroids should be limited to the time needed to achieve the clearing of the lesions, but no longer than one week (see <a class="local">'Recalcitrant dermatitis'</a> below). Emollients can be used liberally. </p><p>There are no randomized trials evaluating the treatment of nonscalp seborrheic dermatitis in infants. A single randomized trial in adults suggested that <a class="drug drug_pediatric" data-topicid="13401" href="/d/drug information/13401.html" rel="external">ketoconazole</a> 2% cream and mid-potency corticosteroids are equally effective. We generally use only low-potency topical corticosteroids for seborrheic dermatitis in infants given the natural history of spontaneous resolution and the potential for systemic absorption of topical corticosteroids. (See  <a class="medical medical_review" href="/d/html/5565.html" rel="external">"Topical corticosteroids: Use and adverse effects", section on 'Use in children'</a>.)</p><p class="headingAnchor" id="H2573302"><span class="h2">Neck folds and other intertriginous areas</span><span class="headingEndMark"> — </span>We suggest that infants with seborrheic dermatitis of the intertriginous areas be treated with a topical azole (<a class="drug drug_pediatric" data-topicid="13401" href="/d/drug information/13401.html" rel="external">ketoconazole</a> 2% cream or other azole preparation, once a day for one to two weeks). In addition, topical creams or ointments containing <a class="drug drug_pediatric" data-topicid="12893" href="/d/drug information/12893.html" rel="external">zinc oxide</a> and/or petrolatum may be applied liberally. Although there are no randomized trials evaluating this therapy, seborrheic dermatitis involving the intertriginous areas is frequently superinfected with <em>Candida albicans</em>. The topical barrier helps to limit skin maceration.</p><p class="headingAnchor" id="H16968893"><span class="h2">Recalcitrant dermatitis</span><span class="headingEndMark"> — </span>If the rash does not improve after one week of corticosteroid therapy or two weeks of antifungal therapy as described above, the diagnosis should be reconsidered. (See <a class="local">'Differential diagnosis'</a> above.)</p><p>If the diagnosis of infantile seborrheic dermatitis is confirmed, intermittent courses of treatment may be needed, since the disease may recur for weeks to months before disappearing.</p><p class="headingAnchor" id="H3613380296"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/116474.html" rel="external">"Society guideline links: Seborrheic dermatitis"</a>.) </p><p class="headingAnchor" id="H13010581"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/82948.html" rel="external">"Patient education: Seborrheic dermatitis (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/7636.html" rel="external">"Patient education: Seborrheic dermatitis (including dandruff and cradle cap) (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H29306861"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology </strong>– Seborrheic dermatitis is a very common and self-limited condition occurring in infants between 3 weeks and 12 months of age, with a peak prevalence at the age of three months. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – In infants, seborrheic dermatitis most frequently involves the scalp (cradle cap  (<a class="graphic graphic_picture graphicRef101268 graphicRef101267" href="/d/graphic/101268.html" rel="external">picture 1A-B</a>)) but may involve the face and neck  (<a class="graphic graphic_picture graphicRef101270 graphicRef130273" href="/d/graphic/101270.html" rel="external">picture 1C-D</a>), the trunk, diaper area  (<a class="graphic graphic_picture graphicRef73813" href="/d/graphic/73813.html" rel="external">picture 3</a>), or multiple sites at the same time  (<a class="graphic graphic_picture graphicRef52803" href="/d/graphic/52803.html" rel="external">picture 4</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cradle cap</strong> – The initial treatment of scalp seborrheic dermatitis includes education, reassurance, and conservative measures (emollients and frequent shampooing) to soften and remove the scales. If conservative measures fail, we suggest either topical low-potency corticosteroids (group 7  (<a class="graphic graphic_table graphicRef62402" href="/d/graphic/62402.html" rel="external">table 1</a>)) or <a class="drug drug_pediatric" data-topicid="13401" href="/d/drug information/13401.html" rel="external">ketoconazole</a> 2% shampoo or cream (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). A topical corticosteroid is applied once per day for one week. Ketoconazole 2% shampoo or cream is used twice per week for two weeks. (See <a class="local">'Cradle cap'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nonscalp, nonintertriginous areas</strong> – For seborrheic dermatitis of areas other than the scalp, we suggest <a class="drug drug_pediatric" data-topicid="13401" href="/d/drug information/13401.html" rel="external">ketoconazole</a> 2% cream or a low-potency corticosteroid cream  (<a class="graphic graphic_table graphicRef62402" href="/d/graphic/62402.html" rel="external">table 1</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Ketoconazole 2% cream should be applied once a day for one to two weeks. A topical corticosteroid is applied once a day for up to one week. (See <a class="local">'Nonscalp, nonintertriginous seborrheic dermatitis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Intertriginous areas</strong> – For seborrheic dermatitis of the intertriginous areas, we suggest <a class="drug drug_pediatric" data-topicid="13401" href="/d/drug information/13401.html" rel="external">ketoconazole</a> 2% cream or other azole cream (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). The azole cream is applied once a day for one to two weeks. In addition, topical creams or ointments containing <a class="drug drug_pediatric" data-topicid="12893" href="/d/drug information/12893.html" rel="external">zinc oxide</a> and/or petrolatum may be applied liberally. (See <a class="local">'Neck folds and other intertriginous areas'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Recalcitrant dermatitis</strong> – If the rash does not resolve or improve considerably after one week of corticosteroid therapy or two weeks of antifungal therapy as described above, the diagnosis should be reconsidered. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent2">If the diagnosis of infantile seborrheic dermatitis is confirmed, intermittent courses of treatment may be needed, since the disease may recur for weeks to months before disappearing.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Sachdeva M, Kaur S, Nagpal M, Dewan SP. Cutaneous lesions in new born. Indian J Dermatol Venereol Leprol 2002; 68:334.</a></li><li><a class="nounderline abstract_t">Foley P, Zuo Y, Plunkett A, et al. The frequency of common skin conditions in preschool-aged children in Australia: seborrheic dermatitis and pityriasis capitis (cradle cap). Arch Dermatol 2003; 139:318.</a></li><li><a class="nounderline abstract_t">Ruiz-Maldonado R, López-Matínez R, Pérez Chavarría EL, et al. Pityrosporum ovale in infantile seborrheic dermatitis. Pediatr Dermatol 1989; 6:16.</a></li><li><a class="nounderline abstract_t">Broberg A, Faergemann J. Infantile seborrhoeic dermatitis and Pityrosporum ovale. Br J Dermatol 1989; 120:359.</a></li><li><a class="nounderline abstract_t">Wananukul S, Chindamporn A, Yumyourn P, et al. Malassezia furfur in infantile seborrheic dermatitis. Asian Pac J Allergy Immunol 2005; 23:101.</a></li><li><a class="nounderline abstract_t">Sarkar R, Garg VK. Erythroderma in children. Indian J Dermatol Venereol Leprol 2010; 76:341.</a></li><li><a class="nounderline abstract_t">Al-Dhalimi MA. Neonatal and infantile erythroderma: a clinical and follow-up study of 42 cases. J Dermatol 2007; 34:302.</a></li><li><a class="nounderline abstract_t">Falusi OO. Seborrhea. Pediatr Rev 2019; 40:93.</a></li><li><a class="nounderline abstract_t">Wannanukul S, Chiabunkana J. Comparative study of 2% ketoconazole cream and 1% hydrocortisone cream in the treatment of infantile seborrheic dermatitis. J Med Assoc Thai 2004; 87 Suppl 2:S68.</a></li><li><a class="nounderline abstract_t">Brodell RT, Patel S, Venglarcik JS, et al. The safety of ketoconazole shampoo for infantile seborrheic dermatitis. Pediatr Dermatol 1998; 15:406.</a></li><li><a class="nounderline abstract_t">Taieb A, Legrain V, Palmier C, et al. Topical ketoconazole for infantile seborrhoeic dermatitis. Dermatologica 1990; 181:26.</a></li><li><a class="nounderline abstract_t">Morra P, Bartle WR, Walker SE, et al. Serum concentrations of salicylic acid following topically applied salicylate derivatives. Ann Pharmacother 1996; 30:935.</a></li></ol></div><div id="topicVersionRevision">Topic 16261 Version 15.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17656992" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Cutaneous lesions in new born.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12622623" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The frequency of common skin conditions in preschool-aged children in Australia: seborrheic dermatitis and pityriasis capitis (cradle cap).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2523039" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Pityrosporum ovale in infantile seborrheic dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2523723" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Infantile seborrhoeic dermatitis and Pityrosporum ovale.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16252839" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Malassezia furfur in infantile seborrheic dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20657113" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Erythroderma in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17408438" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Neonatal and infantile erythroderma: a clinical and follow-up study of 42 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30709979" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Seborrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16083165" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Comparative study of 2% ketoconazole cream and 1% hydrocortisone cream in the treatment of infantile seborrheic dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9796598" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The safety of ketoconazole shampoo for infantile seborrheic dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2144249" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Topical ketoconazole for infantile seborrhoeic dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8876850" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Serum concentrations of salicylic acid following topically applied salicylate derivatives.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
